Hepatic CT enhancement. Part I. Alterations in the volume of contrast material within the same patients

Hepatic enhancement at computed tomography: is there a dependence on body weight past institutional contrast dosing limits?

BACKGROUND

Although described in product monographs, the maximum contrast media (CM) dose at computed tomography (CT) varies among institutions.

PURPOSE

To investigate whether an upper limit of 40 g of iodine in women and 50 g in men is sufficient or if there is a body weight (BW) dependence of mean hepatic enhancement (MHE) beyond those thresholds.

MATERIAL AND METHODS

At our institution, CM injection duration is fixed to 30 s and dosed 600 mg iodine/kg up to 40 g in women and 50 g in men. Pre- and post-contrast hepatic attenuation values (HU) were retrospectively obtained in 200 women and 200 men with glomerular filtration rate >45 mL/min undergoing 18-flurodeoxyglucose PET-CT (18F-FDG PET-CT) of which half weighed below and half above those dose thresholds using iodixanol 320 mg iodine/mL or iomeprol 400 mg iodine/mL. The correlation between BW and MHE was assessed by simple linear regression.

RESULTS

Weight range was 41-120 kg in women and 47-137 kg in men. There was no significant relationship between MHE and BW in women receiving <40 g (r = -0.05, P = 0.63) or in men receiving <50 g (r = 0.18, P = 0.07). Above those thresholds there was an inverse relationship (r = -0.64, P<0.001 in women and r = -0.30, P<0.002 in men). There was no apparent upper limit where the dependence of hepatic MHE on BW decreased. Hepatosteatosis limited MHE.

CONCLUSION

Adjusting CM to BW diminishes the dependence of MHE on BW. There was no apparent upper limit for the relationship between BW and MHE in heavier patients at CM-enhanced CT.

Evaluation of Iodinated Contrast Media Use in Abdominal CT Scans in Cancer Assessments: A Cross-Sectional Study in Lomé (Togo)

Background

There is great variability between centers regarding contrast injection protocols. They should only be injected if they can provide useful information for diagnosis with the necessary and sufficient quantity of iodine. We wanted to know through this study if the use of iodinated contrast media is optimised in abdominal CT scans performed for cancer assessment in Lomé.

Materials and Methods

It was a cross-sectional, descriptive, and analytical study with a prospective collection over a period of 6 months in three CT units in Lomé. It involved abdominal CT scans performed for oncological evaluation. Data were reported as the mean ± standard deviation. The Pearson correlation coefficient, ANOVA, chi-square, and the Fisher test were used.

Results

A total of 218 examinations were recorded. The female sex represented 56.88% of the patients. The mean age was 50.92 ± 15.78 years. The mean weight was 70.46 ± 15.23 kg. The mean BMI was 24.91 ± 5.32 kg/m². The examinations were performed with a voltage of 120 kV in 195 cases (89.45%). The mean dose of injected iodine was 0.42 ± 0.09 gI/kg with a dose of 0.40 gI/kg at 80 kV and 0.45 gI/kg at 130 kV. The mean injection rate was 2.90 ± 0.34 mL/s. The mean injected volume was 83.19 ± 7.29 mL. The mean duration of the injection was 30.60 ± 7.39 s. The mean iodine delivery rate was 0.98 ± 0.17 gI/s. There was no saline injection in 152 cases (69.72%). Liver contrast enhancement was satisfactory in 94.5% of cases. There was a strong negative linear correlation between the dose of injected iodine and weight.

Conclusions

Optimization guidelines for the use of iodinated contrast media are not always applied. Therefore, monitoring and benchmarking programmes for iodinated contrast injection protocols that involve all radiology personnel should be implemented.

Optimization of a protocol for contrast-enhanced four-dimensional computed tomography imaging of thoracic tumors using minimal contrast agent

Purpose

The accuracy of target delineation for node-positive thoracic tumors is dependent on both four-dimensional computed tomography (4D-CT) and contrast-enhanced three-dimensional (3D)-CT images; these scans enable the motion visualization of tumors and delineate the nodal areas. Combining the two techniques would be more effective; however, currently, there is no standard protocol for the contrast media injection parameters for contrast-enhanced 4D-CT (CE-4D-CT) scans because of its long scan durations and complexity. Thus, we aimed to perform quantitative and qualitative assessments of the image quality of single contrast-enhanced 4D-CT scans to simplify this process and improve the accuracy of target delineation in order to replace the standard clinical modality involved in administering radiotherapy for thoracic tumors.

Methods

Ninety consecutive patients with thoracic tumors were randomly and parallelly assigned to one of nine subgroups subjected to CE-4D-CT scans with the administration of contrast agent volume equal to the patient’s weight but different flow rate and scan delay time (protocol A1: flow rate of 2.0 ml/s, delay time of 15 s; A2: 2.0 ml/s, 20 s; A3: 2.0 ml/s, 25 s; B1: 2.5 ml/s, 15 s; B2: 2.5 ml/s, 20 s; B3: 2.5 ml/s, 25 s; C1: 3.0 ml/s, 15 s; C2: 3.0 ml/s, 20 s; C3: 3.0 ml/s, 25 s). The Hounsfield unit (HU) values of the thoracic aorta, pulmonary artery stem, pulmonary veins, carotid artery, and jugular vein were acquired for each protocol. Both quantitative and qualitative image analysis and delineation acceptability were assessed.

Results

The results revealed significant differences among the nine protocols. Enhancement of the vascular structures in mediastinal and perihilar regions was more effective with protocol A1 or A2; however, when interested in the region of superior mediastinum and supraclavicular fossa, protocol C2 or C3 is recommended.

Conclusion

Qualitatively acceptable enhancement on contrast-enhanced 4D-CT images of thoracic tumors can be obtained by varying the flow rate and delay time when minimal contrast agent is used.

Lean body weight versus total body weight to calculate the iodinated contrast media volume in abdominal CT: a randomised controlled trial

Objectives

Iodinated contrast media (ICM) could be more appropriately dosed on patient lean body weight (LBW) than on total body weight (TBW).

Methods

After Ethics Committee approval, trial registration NCT03384979, patients aged ≥ 18 years scheduled for multiphasic abdominal CT were randomised for ICM dose to LBW group (0.63 gI/kg of LBW) or TBW group (0.44 gI/kg of TBW). Abdominal 64-row CT was performed using 120 kVp, 100–200 mAs, rotation time 0.5 s, pitch 1, Iopamidol (370 mgI/mL), and flow rate 3 mL/s. Levene, Mann–Whitney U, and χ² tests were used. The primary endpoint was liver contrast enhancement (LCE).

Results

Of 335 enrolled patients, 17 were screening failures; 44 dropped out after randomisation; 274 patients were analysed (133 LBW group, 141 TBW group). The median age of LBW group (66 years) was slightly lower than that of TBW group (70 years). Although the median ICM-injected volume was comparable between groups, its variability was larger in the former (interquartile range 27 mL versus 21 mL, p = 0.01). The same was for unenhanced liver density (IQR 10 versus 7 HU) (p = 0.02). Median LCE was 40 (35–46) HU in the LBW group and 40 (35–44) HU in the TBW group, without significant difference for median (p = 0.41) and variability (p = 0.23). Suboptimal LCE (< 40 HU) was found in 64/133 (48%) patients in the LBW group and 69/141 (49%) in the TBW group, but no examination needed repeating.

Conclusions

The calculation of the ICM volume to be administered for abdominal CT based on the LBW does not imply a more consistent LCE.

Abdominal CT: a radiologist-driven adjustment of the dose of iodinated contrast agent approaches a calculation per lean body weight

Background

The contrast agent (CA) dose for abdominal computed tomography (CT) is typically based on patient total body weight (TBW), ignoring adipose tissue distribution. We report on our experience of dosing according to the lean body weight (LBW).

Methods

After Ethics Committee approval, we retrospectively screened 219 consecutive patients, 18 being excluded for not matching the inclusion criteria. Thus, 201 were analysed (106 males), all undergoing a contrast-enhanced abdominal CT with iopamidol (370 mgI/mL) or iomeprol (400 mgI/mL). LBW was estimated using validated formulas. Liver contrast-enhancement (CE_L) was measured. Data were reported as mean ± standard deviation. Pearson correlation coefficient, ANOVA, and the Levene test were used.

Results

Mean age was 66 ± 13 years, TBW 72 ± 15 kg, LBW 53 ± 11 kg, and LBW/TBW ratio 74 ± 8%; body mass index was 26 ± 5 kg/m², with 9 underweight patients (4%), 82 normal weight (41%), 76 overweight (38%), and 34 obese (17%). The administered CA dose was 0.46 ± 0.06 gI/kg of TBW, corresponding to 0.63 ± 0.09 gI/kg of LBW. A negative correlation was found between TBW and CA dose (r = -0.683, p < 0.001). CE_L (Hounsfield units) was 51 ± 18 in underweight patients, 44 ± 8 in normal weight, 42 ± 9 in overweight, and 40 ± 6 in obese, with a significant difference for both mean (p = 0.004) and variance (p < 0.001). A low but significant positive correlation was found between CE_L and CA dose in gI per TBW (r = 0.371, p < 0.001) or per LBW (r = 0.333, p < 0.001).

Conclusions

The injected CA dose was highly variable, with obese patients receiving a lower dose than underweight patients, as a radiologist-driven ‘compensation effect’. Diagnostic abdomen CT examinations may be obtained using 0.63 gI/kg of LBW.

Optimization of image quality in pulmonary CT angiography with low dose of contrast material

Aim: The aim of this study was to compare objective image quality data for patient pulmonary embolism between a conventional pulmonary CTA protocol with respect to a novel acquisition protocol performed with optimize radiation dose and less amount of iodinated contrast medium injected to the patients during PE scanning. Materials and Methods: Sixty- four patients with Pulmonary Embolism (PE) possibility, were examined using angio-CT protocol. Patients were randomly assigned to two groups: A (16 women and 16 men, with age ranging from 19-89 years) mean age, 62 years with standard deviation 16; range, 19-89 years) - injected contrast agent: 35-40 ml. B (16 women and 16 men, with age ranging from 28-86 years) - injected contrast agent: 70-80 ml. Other scanning parameters were kept constant. Pulmonary vessel enhancement and image noise were quantified; signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated. Subjective vessel contrast was assessed by two radiologists in consensus. Result: A total of 14 cases of PE (22 %) were found in the evaluated of subjects (nine in group A, and five in group B). All PE cases were detected by the two readers. There was no significant difference in the size or location of the PEs between the two groups, the average image noise was 14 HU for group A and 19 HU for group B. The difference was not statistically significant (p = 0.09). Overall, the SNR and CNR were slightly higher on group B (24.4 and 22.5 respectively) compared with group A (19.4 and 16.4 respectively), but those differences were not statistically significant (p = 0.71 and p = 0.35, respectively). Conclusion and Discussion: Both groups that had been evaluated by pulmonary CTA protocol allow similar image quality to be achieved as compared with each other’s, with optimize care dose for both protocol and contrast volume were reduced by 50 % in new protocol comparing to the conventional protocol.

Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures

BACKGROUND

When the same dose of iodine is given to all patients when performing abdominal computed tomography (CT) there may be a wide inter-individual variation in contrast medium (CM) enhancement of the liver.

PURPOSE

To evaluate if any of the measures body height (BH), body mass index (BMI), lean body mass (LBM), ideal body weight (IBW), and body surface area (BSA) correlated better than body weight (BW) with hepatic enhancement, and to compare the enhancement when using iodixanol and iomeprol.

MATERIAL AND METHODS

One hundred patients referred for standard three-phase CT examination of abdomen were enrolled. Body weight and height were measured at the time of the CT examination. Forty grams of iodine (iodixanol 320 mg I/mL or iomeprol 400 mg I/mL) was injected at a rate of 1.6 g-I/s, followed by a 50 mL saline flush. The late arterial phase was determined by using a semi-automatic smart prep technique with a scan delay of 20 s. The hepatic parenchymal phase started automatically 25 s after the late arterial phase. CM concentration was estimated by placement of regions of interest in aorta (native and late arterial phase) and in liver (native and parenchymal phase).

RESULTS

BW (r = -0.51 and -0.64), LBM (r = -0.54 and -0.59), and BSA (r = -0.54 and -0.65) showed the best correlation coefficients with aortic and hepatic parenchymal enhancement, respectively, without any significant differences between the measures. Comparing iodixanol and iomeprol there was no significant difference in aortic enhancement. The liver enhancement was significantly higher (P < 0.05) using iodixanol than iomeprol.

CONCLUSION

To achieve a consistent hepatic enhancement, CM dose may simply be adjusted to body weight instead of using more complicated calculated parameters based on both weight and height.

Aortic and hepatic enhancement at multidetector CT: evaluation of optimal iodine dose determined by lean body weight

PURPOSE

To determine the optimal iodine dose for aortic and hepatic enhancement at MDCT by comparing lean body weight (LBW) with total body weight (TBW).

MATERIALS AND METHODS

This study was approved by our institutional review committee. One hundred and thirty-six patients were randomized into four groups: 550, 650, 750 mg iodine/(kg of LBW) and 600 mgI/(kg of TBW). The aortic and hepatic contrast enhancements (Δ HUs) during the portal venous-phase and variances of ΔHUs were compared.

RESULTS

Mean ΔHUs for 550, 650, 750 mgI/kg LBW and 600 mgI/kg TBW were: 95.1, 109.9, 122.4, and 131.2HU, respectively, for the aorta. For the liver, 43.1, 55.4, 60.8, and 63.5 HU. Mean Δ HUs increased with iodine dose per kg LBW (p<0.01), but no significant difference between 750 mgI/kg LBW and 600 mgI/kg TBW groups. Hepatic enhancement increased by ≥50 HU in 94% of patients with 750 mg/kg LBW. Variance of hepatic enhancement was marginally greater in the 600 mgI/kg TBW than in the 550 and 750 mgI/kg LBW.

CONCLUSION

Hepatic enhancement variation was reduced with iodine doses based on LBW. Iodine dose of 750 mg iodine/kg LBW was appropriate to achieve hepatic enhancement≥50 HU in 94% of patients.

An optimal contrast dose indicator for the determination of hepatic enhancement in abdominal multidetector computed tomography: comparison of patient attenuation indicator with total body weight and body mass index

PURPOSE

To evaluate a patient attenuation indicator (PAI) as compared with traditional patient-related factors of total body weight and body mass index (BMI) as a predictor of hepatic enhancement in contrast-enhanced abdominal multidetector computed tomography (MDCT).

MATERIALS AND METHODS

Institutional review board approval was obtained, and the study was Health Insurance Portability and Accountability Act compliant. A total of 77 patients (mean age, 53 years; male-female ratio, 32:45) underwent routine contrast-enhanced abdominal CT on a 16-slice multidetector CT (LightSpeed 16; GE Medical Systems, Milwaukee, Wis). Contrast enhancement was achieved by administering a 120-mL iodine contrast medium (350-mg iodine per milliliter) at an injection rate of 3 mL/s followed by an injection of 40-mL saline at 3 mL/s. Computed tomographic attenuation values (Hounsfield units [HU]) of liver parenchyma, main portal vein, and abdominal aorta were measured in each patient. Statistical analysis was performed with linear regression to determine the correlation of PAI, total body weight, and BMI with abdominal organ enhancement.

RESULTS

The mean of PAI, total body weight, and BMI were 28.0 (range, 22.1-34.2), 79.0 kg (range, 49.6-112.2 kg), and 27.5 kg/m (range, 16.8-43 kg/m), respectively. Mean hepatic enhancement was 128.2 HU (range, 73.6-175 HU), mean main portal vein enhancement was 214.2 HU (range, 118-327 HU), and mean abdominal aorta enhancement was 208.9 HU (range, 116-395 HU). Patient attenuation indicator, total body weight, and BMI showed a negative correlation with liver enhancement (r = -0.55, r = -0.4, and r = -0.3, respectively). Patient attenuation indicator exhibited a significantly higher correlation with hepatic enhancement than total body weight and BMI (P < 0.01, respectively).

CONCLUSIONS

Patient attenuation indicator exhibits a moderately inverse correlation with liver enhancement that is greater than those of total body weight and BMI. Patient attenuation indicator may be reliable in predicting the hepatic enhancement degree for a given dose of contrast material and has a potential use in customizing individual patient contrast medium dose during contrast-enhanced abdominal CT.

Intravenous contrast medium administration and scan timing at CT: considerations and approaches

The continuing advances in computed tomographic (CT) technology in the past decades have provided ongoing opportunities to improve CT image quality and clinical practice and discover new clinical CT imaging applications. New CT technology, however, has introduced new challenges in clinical radiology practice. One of the challenges is with intravenous contrast medium administration and scan timing. In this article, contrast medium pharmacokinetics and patient, contrast medium, and CT scanning factors associated with contrast enhancement and scan timing are presented and discussed. Published data from clinical studies of contrast medium and physiology are reviewed and interpreted. Computer simulation data are analyzed to provide an in-depth analysis of various factors associated with contrast enhancement and scan timing. On the basis of basic principles and analysis of the factors, clinical considerations and modifications to protocol design that are necessary to optimize contrast enhancement for common clinical CT applications are proposed.

Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume

PURPOSE

To evaluate and compare total body weight (TBW), lean body weight (LBW), and estimated blood volume (BV) for the adjustment of the iodine dose required for contrast material-enhanced multidetector computed tomography (CT) of the aorta and liver.

MATERIALS AND METHODS

Institutional review committee approval and written informed consent were obtained. One hundred twenty patients (54 men, 66 women; mean age, 64.1 years; range, 19-88 years) who underwent multidetector CT of the upper abdomen were randomized into three groups of 40 patients each: (a) TBW group (0.6 g of iodine per kilogram of TBW), (b) LBW group (0.821 g of iodine per kilogram of LBW), and (c) BV group (men, 8.6 g of iodine per liter of BV; women, 9.9 g of iodine per liter of BV). Change in CT number between unenhanced and contrast-enhanced images per gram of iodine and maximum hepatic enhancement (MHE) adjusted for iodine dose were examined for correlation with TBW, LBW, and BV by using linear regression analysis.

RESULTS

In the portal venous phase, correlation coefficients for the correlation of change in CT number per gram of iodine with TBW for the aorta and liver were -0.71 and -0.79, respectively, in the TBW group; -0.80 and -0.86, respectively, in the LBW group; and -0.68 and -0.66, respectively, in the BV group. In the liver, they were marginally higher in the LBW group than in the BV group (P = .03). Adjusted MHE remained constant at 77.9 HU +/- 10.2 (standard deviation) in the LBW group with respect to TBW, but it increased in the TBW (r = 0.80, P < .001) and BV (r = 0.70, P < .001) groups as TBW increased.

CONCLUSION

When LBW, rather than TBW or BV, is used, the iodine dose required to achieve consistent hepatic enhancement may be estimated more precisely and with reduced patient-to-patient variability.

Hepatocellular carcinomas: correlation between time to peak hepatocellular carcinomas enhancement and time to peak aortic enhancement

PURPOSE

To prospectively assess the relationship between the time to peak enhancement of hepatocellular carcinomas (HCC) and that of the aorta at 64-detector computed tomography (CT).

MATERIALS AND METHODS

The study prospectively included 43 patients with known HCC. All underwent abdominal CT imaging by using BodyPerfusion CT model. The CT data acquisition was initiated with a delay of 8-15s from the beginning of the contrast material administered. The time-density curves (TDC) of the HCC and the aorta were drawn. The times to peak enhancement of the HCC and the aorta were recorded and the correlation between the time to peak enhancement of the HCC and that of the aorta was analyzed.

RESULTS

There were three tendencies of TDC of the HCC enhancement, only 23.3% of them were similar to that of the aorta. The mean time to peak enhancement of the aorta and the HCC (86.1%) was 23.38 s and 30.04 s, respectively. The time to peak enhancement of most HCC was positively and linearly correlated with the time to peak aortic enhancement (r=0.662, P<0.05).

CONCLUSION

The result may potentially allow scan delay optimization at contrast material-enhanced CT image in the detection of HCC according to interindividual variability.

Aortic and hepatic contrast enhancement with abdominal 64-MDCT in pediatric patients: effect of body weight and iodine dose

OBJECTIVE

The purpose of our study was to retrospectively evaluate the effect of body weight and iodine dose on aortic and hepatic contrast enhancement in pediatric patients who underwent 64-MDCT of the abdomen and pelvis.

MATERIALS AND METHODS

Eighty-seven consecutive pediatric patients (50 boys and 37 girls; median age, 12.1 years; age range, 3.8-17.6 years) underwent standard abdominopelvic CT with a 64-MDCT scanner. Contrast medium (350 mg I/mL) was injected using a power injector at 2 mL/s followed by 15-20 mL of saline flush. According to our CT protocol, the volume of administered contrast medium was approximately 1.8 mL/kg of body weight, up to the maximum volume of 80 mL. CT scanning was initiated 60 seconds after the start of the contrast medium injection. CT attenuations of the aorta and liver were measured. For each patient, the injected contrast medium iodine mass per body weight index (g I/kg) (hereafter, iodine mass body index) was calculated. Linear regression analysis was performed between iodine mass body index and aortic and hepatic attenuations.

RESULTS

A wide range of patient weights (19-82 kg; mean, 48.6 kg [95% CI, 45.3-51.9 kg]) and contrast volumes (30-80 mL; median, 80.0 mL) were observed. The median attenuations were 149.0 HU (141.0-160.0 HU) for the aorta and 113.5 HU (109.5-120.0 HU) for the liver. Moderately high correlations were observed between iodine mass body index and aortic (Spearman's rho [r(s)] = 0.60 [0.45-0.72]; p < 0.001) and hepatic (r(s) = 0.60 [0.42-0.70]; p < 0.001) attenuations. The regression formulae for aortic attenuation (58.4 + 176.3 x iodine mass body index [p < 0.001]) and hepatic attenuation (58.7 + 108.5 x iodine mass body index [p < 0.001]) indicate that 1.5 and 1.8 mL/kg (350 mg I/mL) of contrast media are required to achieve 116 and 127 HU, respectively, of contrast-enhanced attenuation in the liver.

CONCLUSION

In our study, using abdominal 64-MDCT in pediatric patients, we found that approximately 1.5 mL/kg, or 0.525 g I/kg, yields 116 HU of hepatic attenuation or 50-55 HU of hepatic enhancement.

Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity

OBJECTIVE

The purpose of our study was to evaluate the effect of body weight, height, body surface area (BSA), body mass index (BMI), and obesity on aortic contrast enhancement in cardiac MDCT.

MATERIALS AND METHODS

Seventy-three consecutive patients underwent cardiac CT angiography on a 64-MDCT scanner. Seventy-five mL of contrast medium (350 mg I/mL) was injected at 4.5 mL/s, followed by a 40-mL saline flush at 4.5 mL/s. The scanning delay of CT was determined with a bolus tracking technique. Aortic attenuation was measured over the aortic-root lumen. BMI and BSA were calculated from the patient's body weight and height. The patients were divided into low-(BMI < 30) and high-(> or = 30) BMI groups. Associations of aortic attenuation with body weight, height, BMI, and BSA were evaluated with regression analysis and the Student's t test.

RESULTS

Strong inverse correlations were seen between aortic attenuation and body weight (r = -0.73), height (r = -0.47), BMI (r = -0.63), and BSA (r = -0.74) (p < 0.001 for all). The regression formula of aortic attenuation versus body weight suggests that 1.0 mL/kg of contrast medium would yield a mean aortic attenuation of 355 H. The mean aortic attenuation was significantly higher in the low-BMI (352.6 +/- 59.1 H) than in the high-BMI (286.2 +/- 55.5 H) group. The regression formula for aortic attenuation on body weight was aortic attenuation = 586-3.1 body weight (p < 0.001) for the low-BMI group and aortic attenuation = 485-1.9 body weight (p < 0.001) for the high-BMI group, suggesting that the amount of contrast medium required with increased body weight is less in the high-BMI group. This group difference was less pronounced for the regression of aortic attenuation on BSA.

CONCLUSION

To achieve a consistent contrast enhancement in cardiac CT angiography (CTA), contrast-medium dose should be adjusted with the body weight or the BSA (which accounts for both the body weight and height factors) to provide adjustment of iodine dose over a wide range of body sizes.

Effect of patient weight and scanning duration on contrast enhancement during pulmonary multidetector CT angiography

PURPOSE

To retrospectively evaluate the amount of contrast medium required with 16- and 64-section computed tomography (CT) for a given patient weight to achieve desirable contrast enhancement during pulmonary CT angiography.

MATERIALS AND METHODS

Institutional review board approval was obtained, and informed consent was not required for this HIPAA-compliant study. Eighty-five patients (35 men, 50 women; range, 22-87 years) who had undergone 16-section (n = 48) or 64-section (n = 37) CT for the detection of pulmonary embolism were retrospectively evaluated. Contrast medium containing 350 mg of iodine per milliliter was injected at a rate of 4 mL/sec. The injected volume corresponded to the injection rate multiplied by the sum of the scanning delay plus the scanning duration, up to 125 mL. The scanning delay was determined with bolus tracking. Contrast enhancement was measured in the main pulmonary artery and the aorta. For each patient, the injected contrast medium volume per body weight index was calculated. Linear regression analysis was performed, and the Wilcoxon signed rank test was used to assess differences between 16- and 64-section CT.

RESULTS

A range of patient weights (45.3-153.0 kg) and contrast medium volumes (76-125 mL) were noted. The regression formula indicated that 1.2 mL per kilogram body weight of contrast medium was required to achieve 250 HU. The median scanning duration was shorter for 64-section CT than for 16-section CT (5.7 seconds vs 9.5 seconds, P < .001). Consequently, 64-section CT required 17.6% less contrast medium than did 16-section CT (85.4 mL vs 103.6 mL, P < .001). Median contrast enhancement in the pulmonary artery was 8.9% lower with 64-section CT than with 16-section CT (257.7 HU vs 282.9 HU, P = .11).

CONCLUSION

To achieve consistent contrast enhancement during pulmonary CT angiography, the amount of contrast medium can be adjusted to the patient's body weight.

Dynamic US contrast study of the liver: Vascular and delayed parenchymal phase

We evaluated the time-intensity curves of the ultrasound contrast agent, Levovist, in the aorta, portal vein and liver parenchyma in order to define distribution of the agent when it is administered by an intravenous bolus injection. Twelve healthy volunteers were studied. All 12 subjects were examined for the study of vascular phase and five of the subjects were examined for the study of delayed parenchymal phase. To evaluate vascular enhancement, transverse abdominal scanning was performed. To evaluate parenchymal enhancement, liver scanning was done just once at 14 time points up to 60 min after injection. The time-intensity curves in the aorta and the portal vein indicated the conventional curves of blood pool agents such as iodine CT agents and gadolinium MRI agents. They showed steep initial rises and peaks at 20 s and 30 s after injection, respectively. Parenchymal enhancement reached a peak five minutes after injection, with a plateau for 20 min subsequently. It has been proved that there are two phases of Levovist contrast ultrasonography, the vascular phase and the delayed parenchymal phase.

Multidetector Multiphase Contrast-enhanced Liver CT

BACKGROUND

To compare 2 rates of contrast material injection, with dose tailored to patient body weight (bw) and automatic bolus triggering system, on vascular and liver parenchyma enhancement at multidetector multiphase contrast-enhanced liver computed tomography (CT) of patients with varied cirrhotic status.

METHODS

One hundred and thirty consecutive patients with varied cirrhotic status, referred for contrast-enhanced liver CT evaluation of focal liver nodule(s), were prospectively and randomly assigned to 1 of 2 routine contrast-enhanced liver CT protocols: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at a 3 mL/sec, versus 2 mL/kg of bw of the same contrast agent injected at 4 mL/sec. Quantitative vascular and liver parenchyma enhancements were obtained. Attenuation values of the abdominal aorta during the arterial phase CT, of the main portal vein during the portal venous phase CT, and of the liver parenchyma during the arterial, the portal venous, and the equilibrium phases liver CT, were compared with multiple 2-way analysis of variance.

RESULTS

Significantly higher attenuation values were noted in the abdominal aorta with a 4-mL/sec-flow rate. Attenuation values were not significantly different in the portal vein and in the liver parenchyma, whatever was the patient cirrhotic status.

CONCLUSIONS

With dose tailored to body weight and automatic bolus triggering system, adjusting flow rate makes no difference in patients with regard to liver or portal vein enhancement, regardless of presence/absence of cirrhosis.

Optimal Delay Time for the Hepatic Parenchymal Enhancement at the Multidetector CT Examination

The objective of this study was to determine the optimal scan delay time after hepatic parenchymal enhancement using a 16-channel multidetector row helical CT (MDCT) scanner. Two hundred fifty-five consecutive patients underwent biphasic CT scans using a 16-channel MDCT. In group A (n = 125), two hepatic venous phase scans (HVP1 and HVP2) were obtained at 40 and 60 seconds, after 100-HU threshold time (T100HU) in the abdominal aorta. In group B (n = 130), HVP1 and HVP2 scans were obtained 50 and 70 seconds after T100HU. Both groups were divided into subgroups that were given different contrast media. Groups A1 and B1 received a contrast medium of 300 mgI/mL; groups A2 and B2 received a contrast medium of 370 mgI/mL. Each patient was injected with contrast medium at a dose of 2 mL/kg at a rate adjusted to the patient's body weight with a constant injection duration of 47 seconds. The attenuation values (HU) for the liver, portal vein, hepatic vein, and aorta were measured. The average HU was compared between the groups. Hepatic enhancement in the images obtained at 50 and 60 seconds after T100HU was greater (P < 0.05) than in images obtained at 40 and 70 seconds. These results were obtained with both contrast media. A few patients showed greater enhancement at a 40 seconds or 70 seconds. Hepatic enhancement was significantly greater in all scans using a contrast medium dose of 370 mgI/mL compared with the 300-mgI/mL dose (P < 0.05). Independent of the concentration of contrast medium, scan delays of 50 to 60 seconds after T100HU may provide optimal hepatic enhancement.

Does iodine concentration affect the diagnostic efficacy of biphasic spiral CT in patients with hepatocellular carcinoma?

BACKGROUND

We investigated the effect of iodinated contrast medium concentration on increased neoplastic lesion enhancement and its direct relation to diagnostic efficacy in biphasic spiral computed tomography for detection of hepatocellular carcinoma.

METHODS

A pilot, single-center, randomized, double-blind, crossover, comparative study was performed and included 22 participants. Each patient underwent two separate biphasic contrast-enhanced spiral computed tomographic examinations. Scans were performed with iomeprol containing 400 (iomeprol 400) or 300 (iomeprol 300) mg of iodine per milliliter (Iomeron, Bracco Imaging SpA, Milan, Italy) with a 2- to 12-day window scan; patients were given an equal total dose of 45 g of iodine at a fixed injection rate of 4 mL/s. Comparison included assessment of quantitative and qualitative parameters.

RESULTS

Lesion density and lesion-to-liver contrast increased more markedly with the higher concentration of contrast medium during the arterial phase (p = 0.0016 and 0.0005, respectively). There was no significant difference in any parameter between the two concentrations during the portal phase. Number of lesions detected during the arterial phase increased from 37 with iomeprol 300 to 42 with iomeprol 400; in the portal phase, the respective numbers were 34 and 36.

CONCLUSION

Even though a small number of patients was examined, our study suggests that, in patients with cirrhosis, an increased concentration of iodine improves liver-to-lesion contrast and may improve the detection of hepatocellular carcinoma.

High-Concentration Contrast Media in Multiphasic Abdominal Multidetector-Row Computed Tomography

OBJECTIVE

The purpose of this study was to assess the influence of the iodine flow rate on parenchymal and vascular enhancement during multiphasic abdominal multidetector-row computed tomography (MDCT).

METHODS

Fifteen patients underwent MDCT at an iodine flow rate of 1.2 g/s as well as 1.6 g/s (group A, protocols 1 and 2), and 90 patients underwent MDCT at an iodine flow rate of 1.2 g/s (group B) or 1.6 g/s (group C). Measurements were performed for all groups in the liver, spleen, pancreas, portal vein, inferior vena cava, and abdominal aorta.

RESULTS

Aortal and pancreatic enhancement during the arterial phase was significantly higher with the higher iodine flow rate. The mean difference in aortal enhancement was 60 Hounsfield units (HU) between protocols 1 and 2 of group A, and the mean difference was 70 HU between groups B and C. The mean difference in pancreatic enhancement was 10 HU between protocols 1 and 2 of group A and 17 HU between groups B and C. During the portal and hepatic venous phases, no significant difference in enhancement was observed.

CONCLUSION

A high iodine flow rate in multiphasic abdominal MDCT improves enhancement of the aorta and the pancreas during the arterial phase but does not influence later phases.

Hepatic enhancement in multiphasic contrast-enhanced MDCT: comparison of high- and low-iodine-concentration contrast medium in same patients with chronic liver disease

OBJECTIVE

The aim of this study was to evaluate the degree of hepatic enhancement and image quality in patients with cirrhosis or chronic hepatitis who underwent multiphasic contrast-enhanced dynamic imaging on MDCT at least twice using standard (300 mg I/mL) and higher (370 mg I/mL) iodine concentrations in contrast medium during follow-up periods.

MATERIALS AND METHODS

This study included 20 patients with chronic liver diseases who underwent at least two multiphasic contrast-enhanced dynamic MDCT examinations using 100 mL of standard (300 mg I/mL = group A) and higher (370 mg I/mL = group B) iodine concentrations in contrast medium. After we obtained unenhanced CT scans, we performed multiphasic scanning at 30 sec (arterial phase), 60 sec (portal phase), and 180 sec (late phase) after the start of contrast medium injection. The CT values of hepatic parenchyma, abdominal aorta, and portal vein were measured. The mean enhancement value was defined as the difference in CT values between unenhanced and contrast-enhanced images. Visual image quality was also assessed on the basis of the degree of hepatic and vascular enhancement, rated on a 4-point scale.

RESULTS

The mean hepatic parenchyma enhancement values in group B was significantly greater (p < 0.001) than those in group A during the portal phase (43.8 +/- 8.2 H vs 36.2 +/- 7.3 H) and the late phase (33.7 +/- 7.0 H vs 27.3 +/- 3.9 H), but the difference on the arterial phase images between the two groups (9.4 +/- 3.2 H vs 8.3 +/- 2.5 H) was not significant. The mean aorta-to-liver contrast during the arterial phase in group B was significantly higher (p < 0.001) than that in group A (236 +/- 40 H vs 193 +/- 32 H). For qualitative analysis, the mean visual scores for hepatic parenchyma and vasculature enhancement in group B were significantly higher than those in group A in arterial phase (p < 0.018), portal phase (p < 0.0001), and late phase (p < 0.0001).

CONCLUSION

In the same patients with chronic liver diseases, a higher iodine concentration (370 mg I/mL) in the contrast medium improves contrast enhancement of liver parenchyma in the portal phase and late phase images, improves overall image quality, and helps improve diagnostic accuracy for liver diseases on multiphasic contrast-enhanced dynamic MDCT.

Clinical evaluation of a computer simulated prediction model of contrast enhancement of the liver in spiral CT

OBJECTIVE

A software program was developed simulating a compartmental model of blood circulation based on differential equations. The aim of this study was to compare software-simulated levels of hepatic enhancement with the true values in patients and to test how many patients reach the simulated hepatic enhancement level.

METHODS

As software program the CT application software carebolus 2 (Siemens, Forchheim, Germany) was used. Hepatic contrast-enhancement curves were simulated prior to CT examinations to evaluate a patient specific time delay after contrast application. At the time delay, when the simulation curve showed an enhancement threshold of 40 Hounsfield Units (HU), the CT spiral scan was started applying 120 ml contrast media with 2 ml/s. The simulated curves were compared with the empiric curves of each patient.

RESULTS

25 of 28 patients (89%) achieved 40 HU. The mean enhancement of empiric patients curves was 46.32 +/- 11.9 HU, the mean simulated enhancement was 46.62 +/- 4.3 HU S.D. (P= 0.48). 4.4 values per patient liver could be compared with the simulation curve (122 points for 28 patients): 50% of the patient curves were within a range of 5 HU compared with the simulation curve.

CONCLUSION

Software simulation of contrast enhancement curves of the liver is a feasible and valuable method to predict individual liver enhancement curves. Improvements concerning the integration of cardiovascular parameters and preexisting liver parenchymal diseases into the simulation software have to be arranged.

Abdominal multidetector row computed tomography: reduction of cost and contrast material dose using saline flush

OBJECTIVE

To evaluate the potential of a saline solution flush after the contrast material bolus in abdominal multidetector row CT (MDCT) in contrast material dose and cost reduction.

METHODS

Abdominal MDCT was performed in 78 patients who were assigned randomly to 2 groups receiving 120 mL nonionic contrast material (300 mgI/mL) alone or 100 mL of the same contrast material pushed with 40 mL of saline solution. Mean attenuation values for both groups were measured in the liver, the spleen, the pancreas, the portal vein, the inferior vena cava, and the abdominal aorta. Cost analyses were performed for both groups.

RESULTS

There was no significant difference in parenchymal and vascular enhancement between both groups. The difference of the enhancement was 2 HU for the liver (P = 0.11), 2 HU for the spleen (P = 0.44), 3 HU for the pancreas (P = 0.38), 9 HU for the portal vein (P = 0.11), 3 HU for the inferior vena cava (P = 0.55), and 10 HU for the aorta (P = 0.06). Taking the costs of contrast material, saline solution, and disposal material into account, 7.30 dollars was saved by the patient using a saline solution flush.

CONCLUSIONS

Using a saline flush after the contrast material bolus in abdominal MDCT allows an iodine dose reduction of approximately 6 g, or 17%, without impairing mean parenchymal and vascular enhancement and a cost reduction of 7.30 dollars per patient.

Improvement of parenchymal and vascular enhancement using saline flush and power injection for multiple-detector-row abdominal CT

The aim of this study was to determine if a saline solution flush following low dose contrast material bolus improves parenchymal and vascular enhancement during abdominal multiple detector-row computed tomography (MDCT). Forty-one patients (24 men and 17 women; mean age 49 years, age range 27-86 years) underwent abdominal MDCT (collimation 4x5 mm, 15-mm table increment, reconstruction interval 5 mm, gantry rotation period 0.8 s) with a single- as well as with a double syringe power injector. Indication for examination were benign and malignant tumors and inflammatory diseases. Patients received 100 ml nonionic contrast material (300 mgI/ml) alone or pushed with 20 ml saline solution. Mean enhancement values for both protocols were measured in the liver, the spleen, the pancreas, the renal cortex, the portal vein, the inferior vena cava and the abdominal aorta. Double syringe power-injector protocol led to significantly higher parenchymal and vascular enhancement than single syringe power-injector protocol (p<0.05). The improvement in mean enhancement of the liver was 9 +/- 9 HU, of the spleen 8 +/- 10 HU, of the pancreas 7 +/- 9 HU, and of the renal cortex 8 +/- 20 HU. The improvement in mean enhancement of the portal vein was 10 +/- 17 HU of the inferior vena cava 8 +/- 13 HU and of the abdominal aorta 10 +/- 17 HU. The use of a double syringe power injector with saline flush following contrast material bolus significantly improves parenchymal and vascular enhancement during contrast-enhanced abdominal MDCT with low iodine doses.

Use of high concentration contrast media (HCCM): principles and rationale--body CT

Numerous complex pharmacokinetic interrelationships affect the use of contrast media for computed tomography (CT) imaging. The volume, concentration, and rate of injection, all affect the degree of enhancement that is achieved with an injection of contrast material. In addition, the injection technique, whether the contrast is infused with a constant injection rate (uniphasic injection) or whether the rate is altered during the injection (multiphasic injection) also affect the magnitude and duration of contrast enhancement. In body CT imaging, the liver poses unique challenges in managing the use of intravenous contrast material because of its dual blood supply and the need to complete imaging before equilibrium occurs between the intravascular and extravascular compartments. The magnitude of hepatic enhancement that is ultimately achieved is related primarily to the amount of iodinated contrast material that accumulates in the extravascular space within the target organ, independent of the speed of the CT scanner. The key determinant of the onset of the equilibrium phase is the injection duration. Given that a high injection flow rate (4-5 ml/s) is desirable for arterial phase imaging, the injection duration is maintained with use of an appropriate contrast volume. Thus, modifications of total iodine dose are best done with alterations in contrast concentration. The magnitude of arterial enhancement that is achieved is related to both the concentration and rate of contrast administration. The speed of the scanner determines its ability to record image data during the most advantageous time period, the peak of arterial enhancement. Thus, rapid imaging is particularly advantageous for optimal contrast use in CT angiography as well as in multiphasic imaging of the parenchymal organs.

Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases--a prospective randomized study in patients with chronic liver damage

PURPOSE

To investigate the optimal imaging delays for hepatic arterial and portal venous phases of gadolinium-enhanced dynamic spoiled gradient-recalled-echo magnetic resonance (MR) imaging of the liver in patients with chronic liver damage.

MATERIALS AND METHODS

MR images were obtained after intravenous bolus injection of gadopentetate dimeglumine in 100 patients with chronic liver damage. Test bolus imaging was performed to determine the aortic transit time. A 26-second spoiled gradient-recalled-echo sequence was used. Patients were randomized into four groups so that the middle of k space was acquired at 5, 10, 15, and 20 seconds for the first phase and 45, 50, 55, and 60 seconds for the second phase, respectively, from the time of arrival of contrast material in the abdominal aorta. Mean signal intensities of the liver, spleen, and abdominal aorta were measured, and images were reviewed prospectively by three radiologists in consensus. Analysis of variance, the Scheffé criterion for continuous data, and the Kruskal-Wallis test for categorical data were used for statistical evaluation.

RESULTS

Intense splenic enhancement with the moiré pattern without intense hepatic enhancement occurred at 10-15 seconds. Aortic and splenic enhancement significantly decreased from 45 to 50 seconds (P <.05). Spleen-to-liver contrast-to-noise ratio began to decrease at 20 seconds and decreased constantly over time. Qualitative results correlated well with quantitative results.

CONCLUSION

Biphasic imaging with k space centered at 10-15 and 50 seconds or later after arrival of contrast material in the abdominal aorta may be the optimal technique to obtain ideal contrast enhancement. Empirically, delays of 28-34 and 68 seconds or later after initiating contrast material injection may be effective for biphasic imaging.

Dual-phase versus single-phase helical CT to detect and assess resectability of pancreatic carcinoma

OBJECTIVE

The aim of this study was to compare dual-phase and single-phase helical CT for the detection and assessment of resectability of pancreatic adenocarcinoma.

SUBJECTS AND METHODS

We studied 60 patients (31 men, 29 women; age range, 31-84 years; mean age, 62 years) with suspected pancreatic malignancy. Patients were randomly assigned to one of two groups. For group A (n = 30), unenhanced scans through the liver and pancreas were followed by two separate acquisitions (dual-phase) at 20-25 and at 60-80 sec after IV contrast administration. For group B (n = 30), unenhanced scans were followed by one set of scans (single-phase) acquired caudocranially (from the inferior hepatic margin to the diaphragm) starting 50 sec after IV contrast administration. Two observers independently scored images for the presence of tumor and for assessment of tumor resectability.

RESULTS

Comparison of dual-phase versus single-phase helical CT for tumor detection showed a diagnostic accuracy for observer 1 of 87% and 90%, respectively, and for observer 2, of 90% and 87%, respectively. For both helical CT techniques, the overall agreement between the two observers was 83% (kappa = 0.73 +/- 0.03) for single-phase helical CT and 90% (kappa = 0.89 +/- 0.03) for dual-phase helical CT. The assessment of resectability was affected by the low number of resectable tumors (n = 8).

CONCLUSION

Single-phase helical CT is effective for the diagnosis and assessment of resectability of patients with suspected pancreatic carcinoma. Advantages are the lower radiation dose and fewer images to film and store.

Current techniques of computed tomography. Helical CT, multidetector CT, and 3D reconstruction

The many recent advances in CT technology have secured its position as the modality of choice in routine liver imaging and have improved its performance in several problem-solving applications. In addition, improvements in postprocessing software (e.g., in speed, efficiency, and automated algorithms) have increased their use in clinical practice. Multiplanar reformations, 3D renderings, and high-quality CT angiographic displays have become extremely valuable both in image interpretation and in communicating information to surgeons and referring physicians.

Noninvasive imaging approach to patients with suspected hepatobiliary disease

Technologic advances in ultrasound, computed tomography (CT), and magnetic resonance imaging over the past decade have greatly improved the noninvasive evaluation of the liver and biliary tree. Each imaging modality offers unique and valuable information that aids in the evaluation of the liver and biliary tree. Improved spatial resolution, harmonic imaging, and color and power Doppler have transformed hepatobiliary ultrasound such that it is often the initial examination for many patients. Helical CT permits the characterization of the hepatic parenchyma during multiple phases of contrast enhancement. New rapid magnetic resonance sequences allow images of the liver to be obtained without motion artifact. The multiplanar techniques of magnetic resonance cholangiography allow noninvasive visualization of the biliary and pancreatic ducts. This article reviews the noninvasive imaging approach to patients with suspected hepatobiliary disease.

Discrimination of Small Hepatic Hemangiomas from Hypervascular Malignant Tumors Smaller than 3 cm with Three-Phase Helical CT

PURPOSE

To compare the appearance of small hepatic hemangiomas at nonenhanced and contrast material-enhanced helical computed tomography (CT) with that of small (<3-cm) hypervascular malignant liver tumors and to evaluate the accuracy of multiphase helical CT for differentiating small hemangiomas from small hypervascular malignant tumors.

MATERIALS AND METHODS

Radiologists reviewed multiphase helical CT liver images in 86 patients with 37 hemangiomas and 49 malignant liver tumors. They evaluated lesion type and degree of enhancement for change from arterial to portal venous phase. They rated their confidence in the discrimination of hemangiomas from malignant tumors.

RESULTS

At arterial phase CT, enhancement similar to aortic enhancement was observed in 19%-32% of hemangiomas and 0%-2% of malignant tumors; globular enhancement, in 62%-68% and 4%-12%, respectively. At portal venous phase CT, enhancement similar to blood pool enhancement was observed in 43%-54% of hemangiomas and 4%-14% of malignant tumors; globular enhancement, in 46%-49% and 0%-2%, respectively. For all readers and all phases of enhancement, the area under the receiver operating characteristic curves was 0.81-0.87, indicating that inherent accuracy of CT is high and that there was no significant difference (P >.28) in overall accuracy. Readers diagnosed hemangiomas with 47%-53% mean sensitivity with all enhancement phases and diagnosed malignant lesions with 95% mean specificity.

CONCLUSION

Small hemangiomas frequently show atypical appearances at CT. Two-phase helical CT does not improve sensitivity but does improve specificity for differentiating hemangiomas from hypervascular malignant tumors.

Power injection of contrast media using central venous catheters: feasibility, safety, and efficacy

OBJECTIVE

This study evaluates the feasibility, safety, and efficacy of power-injecting IV contrast media through central venous catheters for CT examinations.

SUBJECTS AND METHODS

Two hundred ninety-five CT examinations were performed during an 18-month period in 225 patients with indwelling central venous catheters. Patients were randomized to power injection either through peripheral IV catheter or through central venous catheter. Feasibility was defined as the percentage of patients with contrast material injected successfully through the randomized access route. Safety was evaluated by comparing patients with complications. Efficacy was evaluated by comparing contrast enhancement of the thoracic aorta, pulmonary artery, abdominal aorta, and liver.

RESULTS

Two hundred nine patients had randomization data recorded. One hundred three (94%) of 109 patients were successfully injected through their indwelling catheter compared with 42 (42%) of 100 through a peripherally placed IV catheter (p < 0.001). After reassignment for unsuccessful access, 174 patients underwent central venous catheter injection, and 51, peripheral IV catheter injection. No statistically significant difference was noted in the complications between the central venous catheter and peripheral IV catheter groups. Enhancement was greater in the thoracic aorta, pulmonary artery, and liver for the peripheral IV catheter group (p < 0.03).

CONCLUSION

Power injection of contrast media through central venous catheters for CT examinations is feasible and safe when set hospital guidelines and injection protocols are followed. This technique provides an acceptable alternative in patients without adequate peripheral IV access when bolus contrast enhancement is desired.

Contrast media in abdominal computed tomography: optimization of delivery methods

OBJECTIVE

To provide a systematic overview of the effects of various parameters on contrast enhancement within the same population, an animal experiment as well as a computer-aided simulation study was performed.

MATERIALS AND METHODS

In an animal experiment, single-level dynamic CT through the liver was performed at 5-second intervals just after the injection of contrast medium for 3 minutes. Combinations of three different amounts (1, 2, 3 mL/kg), concentrations (150, 200, 300 mgI/mL), and injection rates (0.5, 1, 2 mL/sec) were used. The CT number of the aorta (A), portal vein (P) and liver (L) was measured in each image, and time-attenuation curves for A, P and L were thus obtained. The degree of maximum enhancement (Imax) and time to reach peak enhancement (Tmax) of A, P and L were determined, and times to equilibrium (Teq) were analyzed. In the computed-aided simulation model, a program based on the amount, flow, and diffusion coefficient of body fluid in various compartments of the human body was designed. The input variables were the concentrations, volumes and injection rates of the contrast media used. The program generated the time-attenuation curves of A, P and L, as well as liver-to-hepatocellular carcinoma (HCC) contrast curves. On each curve, we calculated and plotted the optimal temporal window (time period above the lower threshold, which in this experiment was 10 Hounsfield units), the total area under the curve above the lower threshold, and the area within the optimal range.

RESULTS

A. Animal Experiment: At a given concentration and injection rate, an increased volume of contrast medium led to increases in Imax A, P and L. In addition, Tmax A, P, L and Teq were prolonged in parallel with increases in injection time The time-attenuation curve shifted upward and to the right. For a given volume and injection rate, an increased concentration of contrast medium increased the degree of aortic, portal and hepatic enhancement, though Tmax A, P and L remained the same. The time-attenuation curve shifted upward. For a given volume and concentration of contrast medium, changes in the injection rate had a prominent effect on aortic enhancement, and that of the portal vein and hepatic parenchyma also showed some increase, though the effect was less prominent. A increased in the rate of contrast injection led to shifting of the time enhancement curve to the left and upward. B. Computer Simulation: At a faster injection rate, there was minimal change in the degree of hepatic attenuation, though the duration of the optimal temporal window decreased. The area between 10 and 30 HU was greatest when contrast media was delivered at a rate of 2-3 mL/sec. Although the total area under the curve increased in proportion to the injection rate, most of this increase was above the upper threshold and thus the temporal window was narrow and the optimal area decreased.

CONCLUSION

Increases in volume, concentration and injection rate all resulted in improved arterial enhancement. If cost was disregarded, increasing the injection volume was the most reliable way of obtaining good quality enhancement. The optimal way of delivering a given amount of contrast medium can be calculated using a computer-based mathematical model.

Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study

PURPOSE

To determine the optimal dose of intravenous contrast material for helical computed tomography (CT) of the abdomen on the basis of patient weight.

MATERIALS AND METHODS

A prospective randomized study of helical CT of the abdomen was performed by using different doses of intravenous contrast material in 221 patients (mean body weight, 57.3 kg) who were assigned randomly to three groups receiving 1.5, 2.0, or 2.5 mL/kg or a fixed dose of 100 mL of iopamidol 300. The degree of enhancement was scored visually. The CT numbers (HU) of the aorta, portal vein, liver, and pancreas were obtained at three levels of the abdomen.

RESULTS

In arterial enhancement, the 2.0 mL/kg, 2.5 mL/kg, and fixed-dose groups were significantly better than the 1.5 mL/kg group, but there was no significant difference among the 2.0 mL/kg, 2.5 mL/kg, or fixed-dose groups. The degree of enhancement of the liver, pancreas, and portal vein increased with larger doses. At visual analysis, hepatic parenchymal enhancement was graded as good or excellent in 64% of the 1.5 mL/kg, 85% of the 2.0 mL/kg, 94% of the 2.5 mL/kg, and 65% of the fixed-dose groups.

CONCLUSION

When dose was tailored to patient weight, the use of 2.0-2.5 mL/kg of intravenous contrast material produced better results than did 1.5 mL/kg or a fixed dose. Arterial enhancement did not differ among the 2.0 mL/kg, 2.5 mL/kg, or fixed-dose groups.

Factors influencing vascular and hepatic enhancement at CT: experimental study on injection protocol using a canine model

PURPOSE

The purpose of this work was to evaluate the effects of contrast medium injection parameters on aortic, portal vein, and hepatic enhancement at spiral CT and to assess optimal injection protocol for hepatic CT.

METHOD

Ten 15 kg dogs underwent single level dynamic CT through the hepatic hilum at 5 s intervals just after the injection of contrast medium for 3 min. With use of different volumes (1, 2, and 3 ml/kg), injection rates (0.5, 1, and 2 ml/s), and concentrations (150, 200, and 300 mg/ml), a total of 270 spiral CT scans were performed. In each scan, time-attenuation curves of aorta, portal vein, and liver were obtained. The degree of maximum contrast enhancement (Imax), time to maximum enhancement (Tmax), and time to equilibrium phase (Teq) for to each injection protocol were analyzed.

RESULTS

Alterations in contrast material volume, injection rate, and concentration had significant impact on contrast enhancement of the liver. With increasing volume of contrast medium, Imax, Tmax, and Teq of aorta, portal vein, and liver increased (p < 0.005). With increasing rate of injection, on the other hand, Imax of aorta and liver increased (p < 0.05), but Tmax and Teq decreased (p < 0.005). Change of concentration of contrast medium had a significant effect on Imax of vessels (p < 0.05).

CONCLUSION

Maximum contrast enhancement of liver and vessels was influenced mainly by injection volume of contrast medium and the time to peak enhancement by injection rate of contrast medium. Under given amounts of contrast medium, therefore, the strategy of increasing volume by dilution and faster injection might give better Imax values without penalty for the duration of an optimal temporal window (Tmax and Teq).

1999 ARRS Executive Council Award. Contrast-enhanced CT of small hypovascular hepatic tumors: effect of lesion enhancement on conspicuity in rabbits. American Roentgen Ray Society

OBJECTIVE

The purpose of this study was to evaluate the effect of lesion enhancement on the conspicuity of small hypovascular hepatic tumors in an animal model.

MATERIALS AND METHODS

Seven VX2 hepatic tumors in five rabbits were imaged. Dynamic contrast-enhanced CT was performed at a single level centered over the lesions at 5-sec intervals for 119 sec after injection of 2 ml/kg i.v. contrast material at 2 ml/sec. Attenuation was measured over time within regions of interest in the tumor and normal liver, aorta, inferior vena cava, and portal vein. Lesion conspicuity, defined as the difference between the attenuation of the uninvolved liver and neoplasm, was calculated.

RESULTS

The mean diameter of the tumors on CT was 10 mm (range, 6-15 mm). The tumors appeared as low-attenuation lesions with progressive enhancement during the arterial phase and early portal phase. Peak mean lesion attenuation was 60 +/- 27 H (enhancement, 23 H) at 64 sec. Peak mean lesion conspicuity was 80 +/- 18 H at 39 sec, occurring 10 sec before the peak mean hepatic attenuation of 135 +/- 15 H (enhancement, 67 H) at 49 sec. Relative lesion conspicuity paralleled relative enhancement of the liver throughout the imaging period.

CONCLUSION

Although low-level tumor enhancement during the arterial phase and early portal phase reduced the conspicuity of small hypovascular tumors in this animal model, our results support the use of maximum liver enhancement as a marker for peak lesion conspicuity.

Effective contrast use in CT angiography and dual-phase hepatic CT performed with a subsecond scanner

OBJECTIVE

To deduce an optimal injection protocol for CT angiography and fast dual-phase hepatic CT.

METHODS

Fifty-two patients underwent fast dual-phase hepatic CT using one of three different injection protocols: A (0.9 g/sec iodine injection rate, 36 g dose); B (1.35 g/sec, 30 g); C (1.6 g/sec, 40 g). Aortic attenuation time curves as well as aorta-to-liver contrast and hepatic enhancement time curves obtained by region of interest measurements along the helical axis were analyzed.

RESULTS

Protocol C revealed a significantly higher peak in aortic attenuation and hepatic enhancement than the other protocols. Approximately 50 seconds after the bolus injection, hepatic enhancement declined to a plateau similar to that seen with the other protocols. In terms of the areas under the curves of the aorta-to-liver contrast and hepatic enhancement dynamics, protocol C was significantly superior to the other protocols.

CONCLUSIONS

A high iodine injection rate realized by a high iodine concentration in conjunction with fast dual-phase scanning (total scan time < 50 seconds) promises to enhance CT angiography and contrast of liver lesions.

Computed tomography scan of the liver

Computed tomography (CT) examination of the liver has continually been improving our understanding and assessment of liver disease since its introduction into clinical practice. The hallmark of the advances in CT imaging has undoubtably been helical CT, which made a great impact on body imaging with its many advantages, the most important being optimization of multiphasic enhanced studies, CT hepatic angiography (CTHA), and CT arterial portography (CTAP). Various applications and protocols of CT imaging rendering advantages and drawbacks to the technique are highlighted in this review article.

Contrast-enhanced hepatic MRI: comparison of half-dose and standard-dose gadolinium DTPA administration in lesion characterization with T1-weighted gradient echo sequences

The objective of this article was to compare half-dose (0.05 mm/kg) gadolinium-enhanced dynamic hepatic MR imaging to standard doses (0.10 mm/kg). Eighteen patients for follow-up hepatic MR received 0.05 mm/kg of gadolinium DTPA dynamically with gradient-echo imaging. Imaging parameters were identical to a 0.10-mm/kg study; patients were imaged during multiple phases of contrast enhancement. Two readers assessed for enhancement patterns and characterization. Quantitative signal-to-noise ratios (S/N) were obtained for abdominal viscera and contrast-to-noise ratios (C/N) were obtained on up to three lesions. No significant difference for the arterial dominant phase (P > 0.05) was found. Significant differences were found in all categories during the portal venous phase (except pancreas) and equilibrium phase (except liver). Lesion C/N ratios were not significant at any point (P > 0.05). Sixty-two out of 64 lesions (97%) were identically characterized. Therefore, half-dose dynamic gadolinium-enhanced MR may have diagnostic value.

Pancreatic CT imaging: effects of different injection rates and doses of contrast material

PURPOSE

To assess the effects of the intravenous injection rate and dose of contrast material on pancreatic computed tomography (CT).

MATERIALS AND METHODS

A total of 126 patients were divided at random into four groups with different injection rates and doses. Groups 1 and 2 underwent injection of 2 mL per kilogram of body weight of 300 mg of iodine per milliliter of contrast material, and groups 3 and 4 underwent injection of 1.5 mL/kg. The injection rate was 5 mL/sec for groups 1 and 3 and 3 mL/sec for groups 2 and 4. Single-level serial CT scanning was performed at the level of the pancreatic head, and the pancreatic enhancement value was calculated.

RESULTS

The maximum pancreatic enhancement value was 99 HU +/- 18 (mean +/- SD) for group 1, 90 HU +/- 18 for group 2, 86 HU +/- 15 for group 3, and 74 HU +/- 13 for group 4. There were significant differences in the maximum pancreatic enhancement value between groups 1 and 2 (P = .045), between groups 3 and 4 (P = .001), between groups 1 and 3 (P = .016), and between groups 2 and 4 (P = .001).

CONCLUSION

Both a higher dose and a faster injection rate increased the maximum pancreatic enhancement value.

Spiral CT angiography of the renal arteries: should a scan delay based on a test bolus injection or a fixed scan delay be used to obtain maximum enhancement of the vessels?

PURPOSE

The purpose of this work was to assess the optimal scan delay for spiral CT angiography (SCTA) of the renal arteries in achieving optimal vascular contrast enhancement and to compare the utility of a delay based on these bolus injection versus that of a fixed scan delay.

METHOD

Seventy patients underwent renal artery SCTA with a 140 ml bolus of contrast agent injected a 3 ml/s. In 35 patients (Group A), a fixed scan delay of 27 s was used; in the other 35 (Group B), the scan delay was based on the transit time (TTest) of a test bolus injection. The scan delays in this group were set at TTest + 5 s (n = 5), TTest + 10 s (n = 8), TTest + 15 s (n = 4), or TTest + 20 s (n = 18). For all 70 patients, the time intervals between TRA (time to scanning the renal arteries) and TMax (time to maximum aortic enhancement after 140 ml bolus injection) were calculated, after which it was determined in which group of patients TRA occurred closest to TMax. Linear regression and mean squared error (MSE) were used for statistical analysis.

RESULTS

For Group A, mean TRA and TMax were 38 and 50 s, respectively. Mean (TRA - TMax) was -12 s with MSE of 185.76. For Group B, mean TRA and Tmax were 45 and 52 s. Mean (TRA - TMax) values were -15, -12, -11, and -1 s for scan delays of TTEST + 5 s, TTEST + 10 s, TTest + 15 s, and TTEST + 20 s, respectively, with MSEs of 253.80, 158.00, 137.50, and 30.00.

CONCLUSION

SCTA of the renal arteries was best performed with a scan delay of TTEST + 20 s. However, analysis of our data showed that similar results could be expected with a delay of 44 s.

CT scan of the liver

Since its inception, CT scan has had a dominant role in hepatic imaging. Recent advances including helical CT scan and bolus-triggered scan initiation software packages have had a significant impact. Issues regarding volume, rate of administration, and type of intravenous contrast are being distilled. Workstations for three-dimensional data reconstructions are producing images that compete with conventional angiography in certain areas, while angiographically assisted CT scan is being refined in others.

CT scan evaluation of blunt hepatic trauma

Information provided by CT scan allows for determination of the extent of liver injury and identification of other nonhepatic abdominal injuries. This information, coupled with clinical assessment, can be used to optimize management. Contrast-enhanced CT scan can monitor progression or resolution of hepatic injuries, detect complications, and guide percutaneous treatment of some complications. This article discusses CT scanning technique; classification, sites, and mechanisms of liver injury; CT scan appearance of liver injury; and complications of hepatic trauma.

Contrast-enhanced spiral CT of the liver: effect of injection time on time to peak hepatic enhancement

PURPOSE

On contrast-enhanced hepatic CT, maximum tumor detection of liver metastases from colorectal cancer is achieved at peak hepatic enhancement. We investigated the relationship between injection time of contrast medium and time to peak hepatic enhancement (TPHE) after the end of injection.

METHOD

One hundred nineteen patients without a cardiovascular disorder were enrolled in this study. Before the spiral CT was performed, a small amount of contrast medium was injected and a single level dynamic CT was performed to evaluate aortic enhancement and to determine the scan start time of the spiral examination. Patients were divided into three groups; contrast medium was injected over 30 s in 40 patients (Group A), 45 s in 39 patients (Group B), and 60 s in 40 patients (Group C). The TPHE after the end of injection was measured, and the difference among the groups was compared using one-way analysis of variance. A p value of <0.05 was considered a statistically significant difference.

RESULTS

The TPHEs of the groups were 25.3 +/- 4.6 s (Group A), 27.0 +/- 5.8 s (Group B), and 24.4 +/- 4.6 s (Group C) and were similar in value. No statistically significant difference was observed (p = 0.067).

CONCLUSION

Hepatic enhancement reaches its peak at approximately 25 s after the end of contrast medium injection irrespective of injection time.

Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications

The purpose of this article is to review the basic principles and clinical applications of dynamic contrast-enhanced MRI in the musculoskeletal system. This method of physiologic imaging provides clinically useful information by depicting tissue vascularization and perfusion, capillary permeability, and composition of the interstitial space. Different imaging, evaluation, and postprocessing techniques are described. The most important applications in the musculoskeletal system are identification of areas of viable tumor for biopsy, tissue characterization, and monitoring of preoperative chemotherapy. Practical guidelines for performing a dynamic contrast-enhanced MR examination are proposed.